SINGAPORE and SAN DIEGO – July 28, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced that Adrian Woolfson, BM BCh, PhD, has joined its Board of Directors and Scientific Advisory Board to help guide the company’s strategy as it expands into drug discovery.
“Dr. Woolfson has a wealth of experience across immuno-oncology, genomic medicine, and drug discovery and development that will be invaluable as we expand the use of our Deep Immunomics platform into new therapeutic areas,” said Choon-Peng Ng, CEO of ImmunoScape. “We are honored to have him join our Board of Directors and look forward to working closely with him.”
Dr. Woolfson has over two decades of biopharmaceutical industry experience across drug discovery, medical affairs and early and late-stage clinical development. He is currently Co-founder, President, and Executive Chairman of Replay, a VC-backed genome writing, gene editing, genome engineering and iPSC cell therapy company based in La Jolla, California.
Prior to co-founding Replay, he served as the Executive Vice President and Head of Research and Development at Sangamo Therapeutics, where he led the first ever in vivo genome editing human study and the development of a first-in-human autologous CAR-Treg platform. While at Sangamo, he also led an allogeneic CAR-T cell collaboration with KITE/Gilead, transitioned the giroctocogene fitelparvovec hemophilia A gene therapy program into a registrational Ph3 (AFFINE Study) led by Pfizer, and played a key role in closing a ~$3B deal with Biogen and a ~$1B deal with Novartis.
Earlier, Dr. Woolfson was Global Clinical Leader of Early and Late-Stage Immuno-Oncology/Hematology at Pfizer in New York, where he led the registrational Ph3 of Pfizer’s SMO inhibitor Daurismo and established a portfolio of I-O studies for Pfizer’s PD-L1 inhibitor Bavencio. He also served as Global Clinical Lead in Oncology at Bristol-Myers Squibb in Princeton, where amongst other things, he led the development of novel SMO, CDC7, and JAK2 inhibitors.
Dr. Woolfson completed his undergraduate medical training at King’s College, UK, where he was awarded the Jelf Medal. He then completed his clinical medical training at the John Radcliffe Hospital in Oxford, UK and his post-graduate medical training at Addenbrooke’s Hospital in Cambridge, UK. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge and a Wellcome Trust Research Fellow at the MRC Laboratory of Molecular Biology in Cambridge, UK where he worked with the inventor of monoclonal antibodies and Nobel Prizewinner César Milstein. Dr. Woolfson has authored over 100 publications and is the named inventor on several patents including a method for refolding proteins and the first ever I-O triplet therapy.
Dr. Woolfson joins a Board of Directors comprising Choon-Peng Ng, CEO of ImmunoScape, Alessandra Nardin, DVM, COO of ImmunoScape, Naonori (Nori) Kurokawa, Partner at UTEC, and David Michael, Managing Partner of Anzu Partners.
“I am excited to be joining the ImmunoScape Board of Directors during this period of growth for the Company where the Deep Immunomics technology platform is expanding its potential,” said Dr. Woolfson. “I look forward to working alongside my business and scientific colleagues on the board to continue to raise ImmunoScape’s profile in the biopharmaceutical industry.”
To learn more about ImmunoScape please visit https://immunoscape.com/.
ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. For more information, please visit https://immunoscape.com/.
Kalyn Schieffer for ImmunoScape